Systemic Disease-Induced Salivary Biomarker Profiles in Mouse Models of Melanoma and Non-Small Cell Lung Cancer by Gao, Kai et al.
Systemic Disease-Induced Salivary Biomarker Profiles in
Mouse Models of Melanoma and Non-Small Cell Lung
Cancer
Kai Gao
1, Hui Zhou
1, Lei Zhang
1, Jin Wook Lee
2, Qing Zhou
2, Shen Hu
1, Lawrence E. Wolinsky
5, James
Farrell
6, Guido Eibl
7, David T. Wong
1,3,4,5,8*
1School of Dentistry & Dental Research Institute, University of California Los Angeles, Los Angeles, California, United States of America, 2Department of Statistics,
University of California Los Angeles, Los Angeles, California, United States of America, 3Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los
Angeles, California, United States of America, 4Molecular Biology Institute, University of California Los Angeles, Los Angeles, California, United States of America,
5Division of Oral Biology, University of California Los Angeles, Los Angeles, California, United States of America, 6Department of Digestive Diseases, University of
California Los Angeles, Los Angeles, California, United States of America, 7Department of General Surgery, David Geffen School of Medicine, University of California Los
Angeles, Los Angeles, California, United States of America, 8Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles,
California, United States of America
Abstract
Background: Saliva (oral fluids) is an emerging biofluid poised for detection of clinical diseases. Although the rationale for
oral diseases applications (e.g. oral cancer) is intuitive, the rationale and relationship between systemic diseases and saliva
biomarkers are unclear.
Methodology/Principal Findings: In this study, we used mouse models of melanoma and non-small cell lung cancer and
compared the transcriptome biomarker profiles of tumor-bearing mice to those of control mice. Microarray analysis showed
that salivary transcriptomes were significantly altered in tumor-bearing mice vs. controls. Significant overlapping among
transcriptomes of mouse tumors, serum, salivary glands and saliva suggests that salivary biomarkers have multiple origins.
Furthermore, we identified that the expression of two groups of significantly altered transcription factors (TFs) Runx1,
Mlxipl, Trim30 and Egr1, Tbx1, Nr1d1 in salivary gland tissue of melanoma-bearing mice can potentially be responsible for
82.6% of the up-regulated gene expression and 62.5% of the down-regulated gene expression, respectively, in the saliva of
melanoma-bearing mice. We also showed that the ectopic production of nerve growth factor (NGF) in the melanoma tumor
tissue as a tumor-released mediator can induce expression of the TF Egr-1 in the salivary gland.
Conclusions: Taken together, our data support the conclusion that upon systemic disease development, significant changes
can occur in the salivary biomarker profile. Although the origins of the disease-induced salivary biomarkers may be both
systemic and local, stimulation of salivary gland by mediators released from remote tumors plays an important role in
regulating the salivary surrogate biomarker profiles.
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Introduction
Saliva harbors a wide spectrum of proteins/peptides, nucleic
acids, electrolytes, and hormones that originate in multiple local
and systemic sources. The biochemical and physicochemical
properties of saliva support its important functions in oral health
such as food digestion, antibacterial activity, and maintenance of
the integrity of the teeth [1,2]. For example, xerostomia is an oral
disease caused by a dysfunction of salivary glands, which is
accompanied by reduced or absent secretion of saliva and is the
cause of rampant caries and mucositis.
Diagnostically, a number of findings in the past decade have
prompted interest in the use of saliva as a source of biomarkers.
The soluble fragment of c-erbB-2 was detectable in the saliva of
breast cancer patients but not in healthy controls or patients
bearing benign tumors [3]. Levels of hormones (e.g. cortisol,
oxytocin) and drugs (e.g. cisplatin, nicotine, methadone) in saliva
reflect their concentration in serum [4,5,6]. In 2004 saliva-based
HIV detection was approved by the US Food and Drug
Administration (FDA).
A significant boost to the scientific foundation and infrastructure
ofsalivarydiagnosticsresearchcamesixyearsago whentheNational
Institute of Dental & Craniofacial Research (NIDCR) made a
significant investment toward developing the use of saliva as a
diagnostic tool. Saliva has since become a biofluid that is poised for
translational and clinical applications. Of note is the maturation of
the salivary proteome, the first implement in the diagnostic toolbox
forsaliva-baseddiagnostics.Wenowknowthereare1166proteinsin
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to participation in diverse biological processes [7]. A second
diagnostic resource in saliva has since emerged, the salivary
transcriptome. Using the salivary transcriptome as a diagnostic tool,
a set of 185 mRNAs was identified as ‘‘normal salivary core
transcripts’’ (NSCT) [8]. Moreover, the salivary transcriptome has
been demonstrated to be clinically discriminatory for detecting oral
cancer and Sjo ¨gren’s syndrome (SS). The combination of seven
salivary transcripts biomarkers (IL8, IL1B, DUSP1, HA3, OAZ1,
S100P, and SAT) can be used to distinguish between the saliva of
patients with oral squamous cell carcinoma (OSCC) and that of
controls with 91% sensitivity and specificity [9]; whereas five salivary
proteomic markers (M2BP, CD59, Catalase, MRP-14 and Profilin)
collectively show a 93% sensitivity and specificity respectively to
detect oral cancer using saliva [10]. Another study showed that 27
mRNAs and 16 peptides in saliva samples of SS patients were
significantly up- or down-regulated [11]. The technology of salivary
transcriptome has recently been advanced to the exon level with the
capacity to comprehensively profile the salivary transcriptome using
an exon-based technology [12].
There are many advantages to use saliva as a clinical diagnostic
biofluid. Sample collection is simple, non-invasive, and causes little
anxiety on the part of patients. The use of saliva also offers a cost-
effective approach for large-scale screens [6].
The use of saliva for detection of oral diseases has been
confirmed, but its use for systemic disease is largely unclear. While
reports have described the detection of biomarkers of systemic
cancer in saliva (e.g. c-erb2 in breast cancer patients), the
mechanisms underlying this phenomenon remain unsubstantiated.
The goal of this study was to explore the scientific evidence and
provide a rationale for the use of saliva for systemic disease
detection. We used syngeneic mouse tumor models to develop
tumors remote from the oral cavity and used the salivary
transcriptome as the biomarker profile readout (Fig. 1). The
salivary transcriptome has been validated as a scientifically
credible and substantiated biomarker source in saliva
[8,9,11,12,13,14,15,16,17], which permits the high throughput
analyses and read-out necessary for the studies.
Results
Significant disease-induced differences between salivary
transcriptome biomarker profiles in tumor-bearing and
control mice
To assess whether the salivary transcriptome biomarker profile
changes upon development of a remote tumor, we performed
microarray analysis to compare the transcriptome biomarker
profiles in saliva of control mice (three groups, 5 mice in each
group) with tumor-bearing (melanoma or lung) mice (three groups,
5 mice in each group) (Fig. 1). It is necessary to have five mice in
each tumor or control group in order to pool sufficient saliva for
RNA isolation. Biomarker selection criteria were set as fold
Figure 1. The Flowchart of animal experiments. Mice (either C57BL/6 mice or DBA/2 mice) were randomly divided into two groups as follows:
control group (control mice) and tumor group (tumor mice) (15 animals per group). PBS was injected into control mice while mice in tumor group
were injected with tumor cells. Tumors establishment took ,3 weeks. Saliva, salivary gland, serum and tumor tissues were collected from each
mouse. Five mice each were pooled into one group and processed to profile their transcriptome by the expression microarrays.
doi:10.1371/journal.pone.0005875.g001
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regulated known genes and 359 significantly down-regulated known
genes (Fig. 2A, Table S3 and S4) in the saliva of melanoma-bearing
mice compared to control mice. Similarly, we found 290
significantly up-regulated transcripts and 784 significantly down-
regulated transcripts (Fig. 2B,.Table S5 and S6) in the saliva of lung
cancer-bearing mice compared to control mice.
We also overlapped the differentiated gene expression in the
saliva of melanoma mice with that of lung cancer mice.
Comparing up-regulated or down-regulated salivary genes in
two models, respectively, we found 11 up-regulated (Fig. 2C) and
17 down-regulated (Fig. 2D) transcripts exist in both models.
However, considering the different genetic background and cancer
cell lines in the two mouse modes, it is not surprised that only a
fraction of total altered genes was overlapped (4.8% (11/225) or
3.8% (11/290) up-regulated genes in melanoma model or lung
cancer model, respectively; 4.2% (17/403) or 2.1% (17/784)
down-regulated transcripts in the two models, respectively).
Figure 2. Expression profilings of saliva in the melanoma and lung cancer mouse models. A, Cluster analysis of 152 up-regulated known
genes (representing 225 probsets, the left panel) and 359 down-regulated known genes (representing 403 probsets, the right panel) differentially
expressed in saliva of melanoma mice vs. control mice (P-value,0.05; fold change $2). The expression profiles were standardized to have zero mean
and unit standard deviation. Red and green represent high and low expression levels after standardization, respectively. B, Cluster analysis of 290 up-
regulated and 784 down-regulated probesets differentially expressed in saliva of lung carcinoma mice vs. control mice (P-value,0.05; fold change
$2). C and D, Overlapping of differentiated gene expression between the melanoma model and lung cancer model. C, overlapping of 225 up-
regulated genes in the melanoma model and 290 up-regulated genes in the lung cancer model. D, overlapping of 403 down-regulated genes in the
melanoma model and 784 down-regulated genes in the lung cancer model.
doi:10.1371/journal.pone.0005875.g002
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salivary mRNA profile alteration
To examine the possible sources contributing to the salivary
transcriptome alterations in mice in response to systemic disease,
we filtered the expression profiling data of the melanoma-bearing
mice (tumor, serum, salivary gland and saliva) to select ‘‘present’’
mRNA with a P value,0.001 and an intensity value.200. In the
melanoma model, 20175, 5493, 19904, and 306 transcripts were
identified in the tumor, serum, salivary gland and saliva,
respectively (Fig. 3A). After overlapping all the present genes
from tumor, serum, salivary gland and saliva, Fig. 3B showed that
of the 306 transcripts present in saliva, 67.6% are also present in
melanoma-tumor tissue, 51.6% are also present in serum and
69.6% are also present in salivary gland. These data indicate that
the origins of the present transcriptome in saliva may be associated
with various compartments in the whole body constituting totally
,75.2% of the 306 salivary transcripts. In addition, 24.8% of the
306 transcripts did not overlap with genes in tumor, salivary gland
and serum, suggesting that they may originate from the oral cavity.
Altered expression of transcription factors (TFs) in
salivary glands of melanoma-bearing mice correlates
with altered transcription factor-mediated gene
expression changes in mouse saliva
Since the salivary transcriptome was clearly altered in tumor-
bearing vs. control mice, we hypothesized that the tumors behave
like endocrine organs in that they secrete mediators (hormones,
lymphokines, cytokines) which can affect the activity of TF in
salivary glands and thereby induce up or down-regulation of
transcripts levels in saliva.
Although the two mouse cancer models in this study are well-
established [34,35], the melanoma mouse model simulates human
melanoma better than lung cancer model theoretically and
pathologically because both human melanoma and this mouse
melanoma occur subcutaneously. Therefore, we used the mela-
noma-bearing C57BL/6 mice as a working model to test our
hypothesis.
We first compared the gene expression profiles of salivary gland
tissues in melanoma-bearing mice with control mice and identified
a list of 46 significantly up-regulated TFs (fold change.2 and
P,0.05) (Table S1). We then calculated the correlation coefficients
between the expression profiles of these significantly altered TFs
and the differentially expressed genes (both up- and down-
regulated) in the saliva of the melanoma-bearing mice. The TFs
were then ranked by the number of highly co-expressed genes
whose correlation with the TF expression is .0.5. The 6 up-
regulated TFs with highest ranking were RunX1 (runt related
transcription factor 1), MLXIPL (musculus MLX interacting
protein-like) and TRIM30 (tripartite motif protein 30) for
upregulated salivary genes and Egr1 (Early growth factor-1),
Tbx1 (T-box 1) and Nr1d1 (musculus nuclear receptor subfamily
1, group D, member 1) for down regulated salivary genes (Fig. 4A,
E, F).
Next, the altered expression patterns of these salivary gland TFs
were validated at both the transcription and protein levels by
qPCR and immunoblotting. Figure 4B shows that the mRNA
levels of the six TFs are increased from 3- to 16- fold in the salivary
glands of melanoma-bearing mice compared to control mice.
Immunoblotting detection using 5 commercially available murine
TFs antibodies revealed 1.5 to 3.5-fold higher levels of these TFs
expression in the salivary glands of melanoma-bearing mice than
in control mice (Figure 4C and 4D). Then Figure 4E and F show
that the above 6 TFs were associated with a number of
differentiated gene expressions in mouse saliva. After overlapping
the associated genes of each TF, it can be seen that the altered
Figure 3. Overlapped gene expression profilings among saliva, salivary gland, serum and tumor in the melanoma mouse model. A,
Overlapping transcripts present in saliva, salivary gland, serum and tumor in the melanoma-bearing mice. B, Of the 306 salivary transcripts, 69.6%
were present in salivary gland, 51.6% present in serum, 67.6% present in tumor (melanoma), and 24.8% may originate from oral cavity (local).
doi:10.1371/journal.pone.0005875.g003
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genes in saliva of the melanoma mouse model. A, The 6 TFs (Runx1, Trim30, Mlxipl, Egr1, Nr1d1, TBX1) are significantly expressed higher in the
salivary gland of melanoma-bearing mice vs. control mice (P,0.05, Table S1). B, mRNA expression levels of these 6 TFs (Runx1, Trim30, Mlxipl, Egr1,
Nr1d1, TBX1) in the salivary gland of melanoma mice vs. that of normal mice validated by qRCR. The horizontal dashed line indicates the levels of
gene expression in control mice, which is arbitrarily set to 1. The columns represent gene expression levels in the salivary gland of melanoma mice
relative to control mice. Experiments were done in triplicates; bars, SD. C, Expression levels of five TFs (Runx1, Mlxipl, Egr1, Nr1d1, and TBX1) in the
salivary gland tissues of control mice and melanoma mice were measured by immunoblotting. (C1, C2, C3 and T1, T2, T3 are the same batch of tissues
used in the microarray assay). Note that commercial antibody was not available for murine Trim30. D, Relative protein expression levels of the above
five TFs in melanoma mice vs. control mice. Signal intensity of the blot in Figure 4C was quantified by Image J software (NIH). The horizontal dashed
line indicates the expression levels of these 5 TFs in control mice, which is arbitrarily set to 1. Columns show that the relative protein levels of the 5
TFs in tumor-bearing mice comparing to control mice; bars, SD. E and F, The expression of 6 TFs (Runx1, Trim30, Mlxipl, Egr1, Nr1d1, TBX1) in the
salivary gland of melanoma mice were correlated with differentiated gene expression in the mouse saliva. Three of them (Runx1, Trim30 and Mlxipl)
Systemic Disease, Saliva Marker
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be potentially responsible for 83% of the up-regulated mRNAs in
saliva (Fig. 4G) whereas the collective altered activities of Egr1,
Tbx1 and Nr1d1 can potentially account for 63% of the down-
regulated expression of salivary mRNAs (Fig. 4H).
The Egr-1 signal pathway and detection of nerve growth
factor (NGF) in melanoma tumor tissue and serum
To investigate whether the developed tumors can mediate the
altered expression of TFs in the salivary glands of tumor-bearing
mice, we examined the NGF/Egr1 signal pathway because Egr1
was identified as an up-regulated TF in the salivary gland of
melanoma-tumor mice. It is well-known that Egr-1 is a TF in the
NGF signaling pathway [18,19] (Fig. 5A). We therefore hypoth-
esize that NGF is secreted into the circulation by the melanoma,
circulates to the salivary gland where it activates the receptor-
mediated signaling cascade leading to Egr-1 upregulation and
induction of specific gene transcription and protein translation.
Figure 5B shows that NGF is produced in melanoma tissue at a
significantly higher levels than in normal skin (P,0.001). Figure 5C
shows that NGF is also significantly higher in the serum of
melanoma-bearing mice compared to control mice (P,0.05).
Collectively these data suggest that melanoma can produce NGF
and is secreted it into the bloodstream. Upon reaching the salivary
glands, the increased NGF levels in the blood could then stimulate
the increased expression of TFs such as Egr-1 leading to altered
gene expression and protein profiles in the saliva of melanoma-
bearing mice.
Discussion
Studies have demonstrated the potential for use of saliva as a
diagnostic biofluid in translational and clinical applications. As a
biological sample, saliva is inexpensive and easily accessible by
non-invasive means. The comprehensive knowledge base of the
saliva’s diagnostic composition offers a valuable and informative
resource for biomarker discovery (www.skb.ucla.edu). Highly
discriminatory salivary biomarkers for two oral diseases: oral
cancer and Sjo ¨gren’s syndrome have been identified and validated
[9,11]. However, the link between systemic diseases and saliva
biomarkers is still unclear. In this study, we used mouse models of
cancer to determine whether salivary biomarker profiles are
affected by distal disease development. Our data demonstrated
that salivary transcriptome profiles are significantly altered in mice
bearing either of two tumors: melanoma and lung carcinoma
(Fig. 2). Each tumor-type was associated with a different salivary
transcriptome profile. In addition, our analysis of NGF production
and the TF Egr1 suggest that the production of growth factors in
the tumor tissue represents one mechanism whereby a distant
tumor can alter the transcriptome of the salivary gland and hence
can be potentially responsible for 180, 35 and 16 of the up-regulated salivary transcripts in melanoma mice (P,0.05), respectively, while the other 3
TFs (Egr1, Tbx1 and Nr1d1) are potentially correlated with 119, 116 and 77 down-regulated salivary transcripts (P,0.05). G, The expression of the 3 TFs
(Runx1, Trim30 and Mlxipl) totally correlated with 82.6% ((180+5+1)/225=82.6%) up-regulated gene expression in melanoma mouse saliva by
overlapping all salivary genes which are correlated with these 3 TFs from Fig. 4E. H, The expression of the other 3 TFs (Egr1, TBX1 and Nr1d1) totally
correlated with 62.5% ((119+58+2+73)/403=62.5%) down-regulated gene expression in the saliva of melanoma mice by overlapping all salivary
genes which are correlated with these 3 TFs from Fig. 4F.
doi:10.1371/journal.pone.0005875.g004
Figure 5. NGF was involved in the activation of TF Egr-1 and increased in the mouse serum. A, A pathway involving transcription factor
Egr1. Nerve growth factor (NGF) can be an upstream factor of Egr1. B, Expression of NGF in mice skin and melanoma tissues measured by ELISA.
Columns are absolute mean values of NGF concentration in tissues from five melanoma mice. ***, P,0.001. C, Expression of NGF in serum of control
mice and tumor mice. Columns are absolute mean values of NGF concentration in serum from five control mice and five melanoma mice. Bar, SD. **,
P,0.05
doi:10.1371/journal.pone.0005875.g005
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play a key role in mediating tumor-induced alterations in saliva
transcriptome biomarker profile. In addition to showing that
disease-induced circulating biomarkers can find their way into the
saliva, these findings suggest that disease-induced salivary gland
surrogate biomarkers can have diagnostic value for the detection
or monitoring of systemic diseases.
Since our first report on the salivary transcriptome [8,9], we
have been examining the origins of salivary mRNA, which appears
to be different from the mRNAs found in other bodily fluids. The
nucleic acids in serum of cancer patients are thought to be shed
directly from the cancer cells or to be released as the result of cell
lysis in damaged organs while the nucleic acids in urine may come
from blood mRNA or DNA [20,21]. In a study of human saliva,
transcripts in the salivary transcriptome can be detected in all
sources of saliva including the parotid gland, submandibular and
sublingual glands, gingival crevicular fluids and oral epithelial cells
[16]. It has recently been demonstrated that the majority of
mRNAs in the salivary transcriptome has an AU-rich element
(ARE) in their 39UTR which confers stability by complexing with
ARE-binding proteins [17]. In the present study, we compared the
transcriptomes of the tumor, serum, salivary glands and saliva and
found the salivary transcriptome in tumor-bearing mice highly
overlapped to a great extent with the transcriptomes of salivary
gland, serum and tumor. These analyses suggest that there may be
multiple origins of salivary mRNA and/or that a complex systemic
relationship may exist between the oral cavity and systemic health.
We investigated potential mechanisms by which the distal
tumors mediate changes in salivary biomarker profiles in tumor-
bearing mice. Previous studies have shown that systemic diseases
or treatments can affect the function of the salivary gland resulting
in changes in the composition of the saliva [22,23,24]. Salivary
sodium and protein levels were elevated after interleukin-2 (IL-2)
treatment in patients. One study using a mouse model also showed
that levels of inflammatory factors such as IL-1beta increased in
saliva after remote inflammation in the body [24]. As the salivary
gland is the major source of saliva, we hypothesized that the
salivary glands can be responsible for saliva specific biomarker
alterations related to distal tumors. Since our experiment was
carried out in triplicate, the Bayesian method may be applicable.
However, this method requires specific model assumptions for the
data. Finally the Expression console (Affymetrix, Inc.) and Dchip
(http://biosun1.harvard.edu/complab/dchip/) software were ap-
plied in this study. For the melanoma syngeneic model, we
identified 46 TFs are significantly up-regulated in the salivary
glands of the melanoma-bearing mice which may lead to direct
induction or suppression of gene expression. The relative fold
changes of TF expression such as Egr1 and Nr1d1 are different
between mRNA levels and protein levels, which may reflect
translational modification or proteasomal degradation [25]. We
then found that these altered expression of TFs is associated with
the melanoma-induced transcriptome in saliva. We found that
approximately 83% of the significantly up-regulated transcripts in
the saliva can be accounted for by three TFs (Runx1, Trim30 and
Mlxipl) (Fig. 4G) and 63% of the significantly down-regulated
salivary transcripts can be accounted for by another three TFs
(Egr1, TBX1 and Nr1d1) (Fig. 4H). Collectively these findings
allow us to conclude that the salivary glands serve a previously
unappreciated role as an organ monitoring systemic disease by
inducing disease-specific TFs and altering expression of specific
genes and translation of the corresponding proteins. These altered
salivary mRNAs and proteins are disease-associated surrogate
biomarkers that are secreted into glandular fluids and enter the
oral cavity as whole saliva.
Since the induction of TFs expression in the salivary glands
occurred in mice with a distal tumor, we further hypothesized
there are tumor-specific mediators that can effect the altered TG
expression in the salivary glands. It is well-known that tumors
ectopically express mediators that have systemic effects on distal
organs and facilitate metastasis of cancer cells [26,27]. Melanomas
are known to ectopically express TGF-beta [28] while lung tumors
ectopically express gonadotropins and other hormones [29,30].
We investigated if one such signaling pathway can related to one of
the identified TFs that can be responsible for induction or
suppression of the salivary transcriptome in the mouse melanoma
model. Indeed, NGF is known to stimulate expression of the TF
Egr-1 through a well-studied signaling pathway (Fig. 5A). Using an
NGF ELISA assay, we observed that the concentration of NGF in
melanoma tissue and serum is significantly higher than in
counterpart control tissues (Fig. 5B, C). These data suggest a
biological scenario and rationale in which the developing mouse
tumor secretes NGF into the circulation, where it circulates in the
blood to the salivary glands and binds to NGF receptors expressed
by salivary acinar cells, activating a signaling pathway that leads to
the upregulation of Egr-1 mRNA and protein levels. It should be
noted that melanoma cells are derived from melanocytes, which
migrate from the neural crest during embryonic development.
NGF can stimulate the proliferation and metastasis of melanoma
cells [31]. On the other hand, NGF and its receptor (TrkA IR and
TrkC IR) have been found in the salivary gland [32,33].
Therefore, it is reasonable to propose that NGF secreted by
melanoma tumor was transferred through blood and bound to its
cognate receptors in the salivary gland, ultimately resulting in the
stimulation of multiple TFs expression including Egr-1 (Fig. 6).
We also measured NGF levels in the tumor lysate of the mouse
lung cancer model. While NGF was detectable, it was at a
significantly lower level than the melanoma tumor lysate
(20.964.3 pg/mg in lung tumor vs. 75.73624 pg/mg in melano-
ma tissue, P,0.05, data not shown). In addition, only 11 up-
regulated and 17 down-regulated transcripts were overlapped
when we compared the salivary mRNA profile of the melanoma
model to the lung cancer model (225 up-regulated or 403 down-
Figure 6. The working model: The relationship between the
salivary transcriptome and the remote tumor. Mediators such as
NGF secreted by remote tumors are transferred to salivary gland
through blood to stimulate TFs expression and alter salivary mRNA
profile.
doi:10.1371/journal.pone.0005875.g006
Systemic Disease, Saliva Marker
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5875regulated genes in the melanoma model vs. 290 up-regulated or
784 down-regulated transcripts in the lung cancer model,
respectively, Fig. 2C and D). And 2 of those 17 overlapped
down-regulated genes were correlated with Egr1 expression (data
not shown). Collectively these data allow us to conclude that
melanoma-derived NGF is a potentially important mediator in the
downregulation of specific salivary transcriptome only in the
melanoma-bearing mice.
While our report does not comprehensively demonstrate the
mechanistic connection between systemic disease development
and salivary biomarker alterations, it does begin to paint the
picture for the concept that systemic networks exist in our body,
which allows communication between distal diseases and the
salivary glands. Signals transmitted through such networks can
induce related signaling pathways that result in altered gene
expression and protein translation and thereby produce disease-
induced salivary biomarker profiles. We hypothesize that such
disease-induced salivary gland-mediated transcriptomes and
translational products can serve as valuable indicators of disease
onset and/or progression. Therefore, the salivary gland can be
considered as a reactive organ monitoring systemic diseases and
saliva can be investigated as a biomarker-enriched disease-
reflective biofluid. The local production and secretion of saliva
from a single anatomical source (the salivary glands), and the fact
that it can be harnessed simply and non-invasively as well as with
relatively little discomfort for patients, provide a strong incentive
for the continued investigation of salvia as a potential diagnostic
indicator of systemic diseases.
Materials and Methods
Animals
Six- to eight-week-old DBA/2 mice and C57BL/6 mice were
purchased from Jackson laboratory (Bar Harbor, ME) and housed
in the Division of Laboratory Animal Medicine (DLAM) at the
University of California at Los Angeles. The experimental protocols
were approved by the Chancellor’s Animal Research Committee
(ARC) at the University of California at Los Angeles (UCLA).
Cell lines
Murine cell lines KLN-205 and B16-F1 were obtained from the
American Type Culture Collection (ATCC). KLN-205 is a non-
small cell lung cancer (NSCLC) cell line originally established in a
DBA/2 mice. Cells were cultured in MEM (GIBCO). And B16-
F1, a C57BL/6–derived melanoma cell line, was maintained in
DMEM (GIBCO) [34]. All cells were maintained in an
atmosphere of 5% CO2 at 37uC.
In vivo tumor models
Melanoma mouse model was induced by subcutaneous (s.c.)
injection of 1610
5 B16-F1 cells in 0.1 ml PBS into the lower-right
flank of C57BL/6 mice. The lung cancer model was established by
s.c. injection of 2610
5 KLN-205 cells in DBA/2 mice [34,35].
Control animals were injected with PBS alone. Established tumors
were observed after 2–3 weeks (Fig. 1).
Collection of mouse saliva, blood and tumor tissue
When tumors reached 15 mm in diameter saliva was collected
and the mice were sacrificed. Mild anesthesia was induced by
intramuscular (IM) injection of 1 ul/kg body weight of a solution
containing 60 mg/ml ketamine (Phoenix Scientific, St. Joseph,
MO) and 8 mg/ml xylazine (Phoenix Scientific). Mice were
subcutaneously injected with pilocarpine (0.05 mg pilocarpine/
100 g body weight) between ears to stimulated saliva secretion.
Saliva was obtained from the oral cavity by micropipette and
immediately placed in pre-chilled 1.5-ml microcentrifuge tubes.
Collection was completed in 20 minutes [23] and samples were
stored at 280uC until analyzed.
Blood was collected in BD Vacutainer tubes containing clot
activator (BD Biosciences) and centrifuged at 10006g for 10 min
after mice were sacrificed[36]. Salivary gland and tumor tissue
were removed from mice, snap-frozen in liquid nitrogen and
stored at 280uC.
The experiment was carried out in triplicate. Mice (either 30
C57BL/6 mice or 30 DBA/2 mice) were randomly assigned to a
control group and a tumor group equally (15 animals per group).
Therefore, in the melanoma mouse model, the control group and
treated group consist of 15 C57BL/6 mice, respectively (totally 30
mice). Saliva sample collected from each of 5 control mice was
designated as C1, 2, 3. Saliva sample pooled from each of 5 treated
mice was designated as T1, 2, 3. The tissue of salivary gland,
serum and tumor was pooled together in the same order. Finally
triplicate samples of each saliva, salivary gland, serum and tumor
tissue in either control group or treated group were ready for the
following RNA extraction and microarray process. We made the
same design in the lung cancer model using 30 DBA/2 mice.
RNA extraction and high-density oligonucleotide
microarray analysis
Saliva, salivary gland, serum and tumor RNA were isolated
using the RNeasy Mini Kit (Qiagen) as described previously [12].
There are 15 mice in the control group or tumor group (totally 30
C57BL/6 mice for melanoma mouse model, another 30 DBA/2
mice for lung cancer mouse model). Samples derived from 5 mice
in each group were pooled and RNA extracted. The pooling is
necessary because it ensures that sufficient salivary mRNA can be
obtained for microarray analyses. Isolated total RNA was treated
with recombinant DNase (Ambion, Austin, TX). For microarray
analysis, mRNA from mouse saliva, gland, serum or tumor was
linearly amplified using the RiboAmp RNA Amplification kit
(Molecular Devices, Sunnyvale, CA). After purification, cDNA
were in vitro transcribed and biotinylated using GeneChip
Expression 39-Amplification Reagents for in vitro transcription
labeling (Affymetrix, Santa Clara, CA). The labeled RNAs (15 ug
each) was subsequently fragmented and sent to UCLA microarray
core facility for array hybridization and scanning. The GeneChip
Mouse Genome 430 2.0 Array, which represents .39,000
transcripts and variants, was used for profiling analysis. All the
raw data were imported into DNA-chip Analyzer software (http://
www.biostat.harvard.edu/complab/dchip) for normalization and
comparison. Microarray data has been uploaded to the GEO
database (http://www.ncbi.nlm.nih.gov/geo/index.cgi). The ac-
cess number is GSE13443
Microarray data analysis
All microarray data were processed and normalized using the
software dChip [37] to compute gene expression indexes. We
conducted two-sample comparisons between gene expression in
the tumor-treated and control groups for salivary gland and saliva,
respectively. A gene was identified as up- (or down-) regulated if 1)
the P-value of the two-sample t-test was ,0.05 and 2) the ratio of
its average expression level in tumor-bearing mice to that in
control mice was .2 (or ,0.5 for down-regulated genes). The
heatmap was created by Cluster3.0 and Java gene Treeview
software [38,39].
Correlation analysis was carried out using expression profiling
in the salivary gland of the melanoma mouse model. Among the
up-regulated genes in salivary gland, 46 of them encode TFs
Systemic Disease, Saliva Marker
PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5875(Table S1). We calculated the correlation coefficients between the
expression profiles of these TFs and the differentially expressed
(up- and down-regulated) genes in saliva in all samples. We ranked
the TFs according to the number of highly coexpressed genes
whose correlation with the TF expression is .0.5.
We also defined a probeset as present when it had a P
value,0.001 and an intensity value.200 [12]. Pathway analysis
was done using the Biocarta database (http://www.biocarta.com)
and permission was obtained for use in the paper.
Quantitative real-time PCR
PCR primers for six genes (Runx1, Trim30 Mlxipl, Egr1,
Nr1d1, and TBX1) (Table S2) were designed using Primer Express
3.0 software (Applied Biosystems, Foster City, CA), with a melting
temperature at 58–60uC. PCR was carried out in triplicate in
reaction volumes of 10 ml using SYBR- Green Master Mix
(Applied Biosystems) for 15 min at 95uC for initial denaturing,
followed by 40 cycles of 95uC for 30 sec and 60uC for 30 sec in the
ABI 7500HT Fast Real Time PCR system [40].
The threshold cycle (Ct) was obtained using the 7500 fast system
software (Applied Biosystems) and was averaged. Relative
expression levels (fold changes) were calculated according to the
formula 2
2[(Te-Tn)-(Ce-Cn)]. Te is the Ct cycle number of an
interested gene such as Runx1 observed in a sample of salivary
gland from the treated group, Tn is the Ct cycle number of the
housekeeping genes GAPDH observed in the same sample while
Ce is the average Ct cycle number of the same target gene such as
Runx1 observed in a sample in the control group, Cn is the
average Ct cycle number of housekeeping gene GAPDH in the
same sample. The results obtained from relative expression levels
were used for statistical analysis. Representative results are shown
in Fig. 5C.
Western blot and ELISA
Tissues were washed in PBS three times and lysed in triple
detergent buffer (50 mM Tris-Cl [pH 8.0], 150 mM NaCl, 0.02%
sodium azide, 0.1% SDS, 100 mg/ml phenylmethylsulphonyl
fluoride, 1 mg/ml aprotinin, 1% Nonidet P-40, and 0.5% sodium
deoxycholate) for 20 min on ice followed by sonication [41]. The
lysate was centrifuged at 12,0006 g for 10 min and the
supernatant was collected. Protein concentration was determined
using the DC Protein Assay (Bio-Rad, Hercules, CA). Proteins
were separated on 10% polyacrylamide/SDS gels (Invitrogen, CA)
and electroblotted onto polyvinylidene difluoride films. Films were
blocked in 5% skimmed milk for 1 h and incubated with the
indicated antibodies (Santa Cruz Biotechnology). (Fig. 5D). The
signal intensity of the bands was measured using Image J software
(NIH, Bethesda, MD). The intensity of a band representing the
interested gene such as Runx1 was divided by the intensity of its
corresponding ACTIN expression on the same blot. Then we
compared the fold changes of each TF expression between the
treated group and the control group (Fig. 5E).
The concentration of NGF in melanoma tissue and serum was
measured by the NGF ELISA kit (Chemicon, Temecula, CA) and
performed according to the manufacturer’s instructions.
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